Rocket Pharma's Pivotal Danon Disease Trial Resumes, KRESLADI™ PDUFA Set for March 28, 2026
RCKT has more than doubled off its 52-week low of $2.19.
Summary
Rocket Pharmaceuticals reported Q4/FY2025 financial results, confirmed its cash runway into Q2 2027, and provided positive updates on its key gene therapy programs, including the resumption of the pivotal Danon disease trial and a PDUFA date for KRESLADI™.
Key Events · Product Development and Regulatory · RCKT
-
Pivotal Danon Disease Trial Resumes
The FDA lifted the clinical hold on the RP-A501 Phase 2 trial for Danon disease in August 2025, with dosing of additional patients anticipated in the first half of 2026.
-
KRESLADI™ PDUFA Date Set
The BLA resubmission for KRESLADI™ (marnetegragene autotemcel) for severe LAD-I has been accepted, with a Prescription Drug User Fee Act (PDUFA) target action date of March 28, 2026.
-
Extended Cash Runway
Rocket Pharmaceuticals reported $188.9 million in cash, cash equivalents, and investments as of December 31, 2025, which is expected to fund operations into the second quarter of 2027.
-
Reduced Operating Expenses
Research and development expenses decreased by $29.2 million and general and administrative expenses decreased by $15.5 million for the twelve months ended December 31, 2025, reflecting disciplined resource allocation and organizational realignment.
Analysis · RCKT · Life Sciences
This filing provides critical updates for Rocket Pharmaceuticals, addressing previous concerns and highlighting significant progress in its pipeline. The resumption of the pivotal Phase 2 trial for RP-A501 in Danon disease, following the lifting of a clinical hold, de-risks a key program. Additionally, the March 28, 2026 PDUFA date for KRESLADI™ creates a near-term catalyst for potential approval and a Priority Review Voucher. The reported cash position and extended operational runway into Q2 2027 provide financial stability, reflecting the impact of recent cost-cutting measures. Investors should monitor the upcoming PDUFA decision and further progress in the Danon disease trial.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1015 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RCKT was trading at $4.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $490.2M. The 52-week trading range was $2.19 to $9.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.